A Pilot Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Latest Information Update: 07 Dec 2022
Price :
$35 *
At a glance
- Drugs 18F-F-AraG (Primary) ; Nivolumab; Pembrolizumab
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics
- Sponsors CellSight Technologies
- 01 Dec 2022 Status changed from recruiting to completed.
- 07 Mar 2022 Planned End Date changed from 1 Jun 2021 to 1 Dec 2022.
- 07 Mar 2022 Planned primary completion date changed from 1 Apr 2021 to 1 Jul 2022.